Abits
ABTS
Digihost Technology
DGHI
Ebang International
EBON
BIT Mining
BTCM
Canaan
CAN
US Stock MarketDetailed Quotes
PPBT Purple Biotech
- 2.776
- +0.020+0.74%
Close Mar 28 16:00 ET
- 2.776
- 0.0000.00%
Post 20:01 ET
7.35MMarket Cap-0.56P/E (TTM)
2.840High2.750Low10.40KVolume2.790Open2.755Pre Close29.02KTurnover0.40%Turnover RatioLossP/E (Static)2.65MShares20.60052wk High0.22P/B7.26MFloat Cap2.00052wk Low--Dividend TTM2.62MShs Float1390.000Historical High--Div YieldTTM3.27%Amplitude2.000Historical Low2.789Avg Price1Lot Size
Market Insights
U.S. Crypto Concept Stocks U.S. Crypto Concept Stocks
Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data. Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data.
Purple Biotech Stock Forum
Purple Biotech Reports Fourth Quarter and Full-Year 2024 Financial Results
Can Purple Biotech's Newly Patented Cancer Drug Combination Tackle Treatment Resistance?
Purple Biotech Granted New U.S. Patent for NT219 in Combination with EGFR Antibody Therapy, Enhancing Global IP Protection in Major Markets
Wednesday, 5th March at 7:00 am
NT219 in combination with EGFR antibody cetuximab (Erbitux) is currently entering a Phase 2 study for head and neck cancer
REHOVOT, Israel, March 05, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-...
Revolutionary Cancer Drug NT219 Enters Phase 2 Trial Targeting $5B Market Opportunity
Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial
Tuesday, 18th February at 7:00 am
NT219, a novel agent designed to overcome tumor resistance to drug therapy, will be evaluated in combination with the standard-of-care head and neck cancer drugs pembrolizumab (Keytruda) or cetuximab (Erbitux)
The study is conducted in collaboration with the University of Colorado Anschutz Medical Campus and is led by Dr. Antonio Jimeno, Professor and Director of ...
Purple Biotech Announces Closing of $2.8 Million Registered Direct Offering of American Depositary Shares
Thursday, 5th December at 7:13 am
REHOVOT, Israel, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that overcome tumor immune evasion and drug resistance, today announced the closing of its previously announced registered direct offering o...
No comment yet